Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms, Second Primary 1Heart Failure 1Cardiotoxicity 1Breast Neoplasms 1Breast Diseases 1

Interventions

Letrozole 20Docetaxel 16Cyclophosphamide 13Zoledronic Acid 12exemestane 11Trastuzumab 11Anastrozole 11Paclitaxel 10Tamoxifen 9Capecitabine 9Fulvestrant 8Epirubicin 8pegfilgrastim 7pertuzumab 6liposomal doxorubicin 6abemaciclib 6Saline Solution 6palbociclib 5Sodium Chloride 5Dexmedetomidine 5Carboplatin 5Bupivacaine 5Bevacizumab 5ribociclib 4pegylated granulocyte colony-stimulating factor 4eribulin 4Tranexamic Acid 4Standard of Care 4Pamidronate 4Filgrastim 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Breast Neoplasms × sacubitril and valsartan sodium hydrate drug combination × Clear all
NCT05465031 2025-03-14

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Silesian Centre for Heart Diseases

Phase 4 Recruiting
600 enrolled
Breast

Breast Diseases, Breast Neoplasms, Heart Failure, Neoplasms, Second Primary, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡